Health Care • Biotechnology: Pharmaceutical Preparations
$4.05 ▲ +0.05
(+1.25%)
MKT CAP: $244.9M • VOL: 2.70M
52W L $4 52W H $10
VNDA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $216.1M | $198.8M | $192.6M |
| YoY Revenue Growth % | +8.7% | +3.2% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$151.2M | -$40.7M | -$14.0M |
| Operating Margin % | -70.0% | -20.5% | -7.2% |
| Net Income (GAAP) | -$220.5M | -$18.9M | $2.5M |
| EBITDA (Normalized) | -$150.4M | -$40.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$109.4M | -$15.8M | $12.8M |
| Capital Expenditures (CapEx) | $998.0K | $490.0K | — |
| Free Cash Flow (FCF) | -$110.4M | -$16.2M | $12.8M |
| FCF Margin % | -51.1% | -8.2% | 6.6% |
| Return on Invested Capital (ROIC %) | -45.0% | -7.4% | — |
| Cash & Short-Term Equivalents | $84.9M | $102.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $327.2M | $538.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VNDA.